Emyria Ltd
Emyria Limited is an Australia-based early-stage drug development company.
The business
Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.
Small Caps Research
No research on Emyria Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise EMD based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Emyria Commences Empax PTSD Care Program at Perth Clinic and Launches Interstate Expansion
Emyria (ASX: EMD) has begun delivering its Empax therapy for post-traumatic stress disorder (PTSD) at a Perth clinic under Australia’s first private health insurance program for psychedelic-assisted treatment. Medibank Private (ASX: MPL) is funding the program under an initial two-year agreement secured in June and will make it available to eligible health fund members. The […]
Emyria’s Empax PTSD trauma care program gains funding support from Medibank Private
Health insurer Medibank Private (ASX: MPL) has commenced funding for eligible members to access the Empax post-traumatic stress disorder (PTSD) care program developed by Emyria (ASX: EMD) and Perth Clinic. The initial two-year agreement marks the first major private health insurance funding of a psychotherapy-led PTSD program in Australia and Emyria regards the move as […]
Emyria and University of Western Australia to research MDMA compounds for treatment of mental health disorders
Clinical drug development and care delivery company Emyria (ASX: EMD) has entered into an agreement with the University of Western Australia (UWA) to examine and expand a unique library of proprietary MDMA-like compounds (or ‘analogues’) developed over the last 10 years. The agreement is considered an important step in investigating the potential of MDMA analogues […]
Emerald Clinics signs cannabis RWE contract with Canopy Growth’s UK subsidiary Spectrum Biomedical
Real-world evidence company Emerald Clinics (ASX: EMD) has hauled in a significant new client in the form of Spectrum Biomedical UK (SBUK), the UK-based subsidiary of the world’s largest cannabis company Canopy Growth, to develop a real-world evidence (RWE) system in the UK. The agreement supplements an existing relationship Emerald has established with Spectrum Therapeutics, […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.